The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma
Hui Zeng(Zhejiang Cancer Hospital), Jingjing Li(Shenyang Ligong University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Cong Luo(Huazhong University of Science and Technology), Lei Zhang(Zhengzhou University), Jinyu Wang(Qingdao University), Xiaoqing Xu(Zhejiang Chinese Medical University), Qi Xu(Zhejiang Cancer Hospital), Jun Luo(Zhejiang Cancer Hospital)
Cited by 17
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412